Key Product Details
Product Summary for Human MAP3K8/Tpl2/COT Antibody
Accession # P41279
Scientific Data Images for Human MAP3K8/Tpl2/COT Antibody
Detection of Human MAP3K8/Tpl2/COT by Western Blot.Western blot shows lysates of Jurkat human acute T cell leukemia cell line and MO7e human megakaryocytic leukemic cell line. PVDF Membrane was probed with 1 µg/mL of Human MAP3K8/Tpl2/COT Monoclonal Antibody (Catalog # MAB4586) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). Specific bands were detected for MAP3K8/Tpl2/COT at approximately 58 and 52 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
Applications for Human MAP3K8/Tpl2/COT Antibody
Sample: Jurkat human acute T cell leukemia cell line and MO7e human megakaryocytic leukemic cell line
Read 1 publication using MAB4586 in the following applications:
Formulation, Preparation and Storage
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
MAP3K8, also called Tpl2 (tumor progression locus 2) or COT (Cancer Osaka Thyroid oncogene) is a cytosolic Ser/Thr kinase. MAP3K8 is one of the MAP kinase kinase (MAPKK) kinases that regulates the ERK1/ERK2 pathway in response to IL-1, facilitating IL-8 and MIP-1 beta production. MAP3K8 activates I kappaB kinases and induces the nuclear production of NF-kappa B. Human MAP3K8 shares 97% and 98% amino acid (aa) identity with mouse and rat MAP3K8, respectively, within the region used as an immunogen. Alternative start sites can give a 58 kDa (467 aa) isoform with stronger activity but shorter half-life than a 52 kDa (397 aa) isoform.
Product Specific Notices for Human MAP3K8/Tpl2/COT Antibody
For research use only